JY231 injection for B-cell acute lymphoblastic leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new injection (JY231) for people with B-cell acute lymphoblastic leukemia (B-ALL) that has not responded well to treatment or has come back. It aims to see if the treatment can help reduce cancer cells in the bone marrow.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are up to 75 years old.
- Your leukemia cells have the CD19 marker on their surface.
- Your bone marrow has more than 5% leukemia cells (blasts) or minimal residual disease (MRD) tests show B-ALL.
- You are in reasonably good health (ECOG score 0, 1, 2, or 3) and expected to live more than 3 months.
- Your liver, kidneys, heart, and lungs are working well enough (based on standard lab tests and heart scans).
- Your blood counts (lymphocytes, platelets, hemoglobin) meet minimum levels, and you have a usable vein for the procedure.
- You do not have active leukemia in your brain or spinal fluid.
- You have not had prior treatment targeting CD19, and no other active cancers (except treated skin or cervical cancer).
- You are not pregnant, breastfeeding, or planning pregnancy in the next 6 months, and you agree to use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment, JY231, for people with B-cell blood cancers that have come back or not responded to other treatments. It aims to see if this therapy can help when other options have stopped working.
This trial tests an investigational drug called JY231 for people with active systemic lupus erythematosus (SLE) that is not well controlled with standard treatments. The goal is to see if JY231 can reduce lupus activity and improve symptoms.
This trial tests a new treatment called JY231 for people with a type of blood cancer (B-cell leukemia) that has come back or not responded to standard treatments. It aims to see if this therapy can help control the cancer.
This trial tests a new cell therapy called JY231 for people whose B-cell lymphoma or leukemia has come back or not responded to standard treatments. The therapy targets a protein on cancer cells called CD19 and may help your immune system fight the cancer.
This trial tests a new cell therapy (JY231) for people whose B-cell lymphoma or leukemia (B-ALL) has returned or not responded to earlier treatments. The therapy uses your own T cells, modified to target the CD19 marker on cancer cells.
This trial tests a new injection called JY231 for people with B-cell lymphoma or leukemia that has come back or not responded to treatment. The therapy targets a protein called CD19 on cancer cells, helping your immune system attack them.
Hear when a new B-cell Acute Lymphoblastic Leukemia (B-ALL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.